
<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  
<!-- Mirrored from investors.scholarrock.com/node/9636/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:07:48 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=UTF-8" /><!-- /Added by HTTrack -->
<head>
    <title>SEC Filing - Scholar Rock, Inc.</title>
    <meta name="robots" content="noindex">
    <link rel="stylesheet" media="all" href="../../sites/g/files/knoqqb56236/files/css/css_-Ogun-b4Vwq8nD6qwBoEYuBhEF_0grnAaUrH4akFvLUcd37.css?delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl" />

    
    <!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='../../../analytics.imirwin.com/js/container_XFyWYf0m.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->

<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-WTGMF33');</script>
<!-- End Google Tag Manager -->

<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="../../../www.googletagmanager.com/nsca0c.html?id=GTM-WTGMF33"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-sec-filing nir-node--9636 page-template-default page page-parent wp-custom-logo wp-embed-responsive full-width-content genesis-breadcrumbs-visible genesis-singular-image-hidden genesis-footer-widgets-visible top-parent-investors-media investors-media has-no-blocks elementor-default elementor-page cbp-spmenu-push cookies-set cookies-accepted body_classes" id="body" cz-shortcut-listen="true">
      <div class="region region-content">
    <div id="block-nir-pid2662-websitenoticeblock" class="block--website-notice-block block--website-notice-block--9636 block--content--website-notice-block block--content--website-notice-block--9636 block--24a64b1d-13aa-4b20-8029-2df59f99a96c block--24a64b1d-13aa-4b20-8029-2df59f99a96c--9636 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2662-content" class="block--system-main-block block--system-main-block--9636 block--content--system-main-block block--content--system-main-block--9636 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0--9636 block block-system block-system-main-block">
  
    
      <div class="nir-sec-header"><div class="logo"><img src="../../sites/g/files/knoqqb56236/files/Logo.png" alt="Scholar Rock, Inc." />
</div><div class="sec-docs">View:  <div class="field ixbrl-link">
    <a href="ixbrl-viewer"></a>
  </div>
  <div class="file-link">
  <span class="file file--mime-application-rtf file--general"> <a href="../../static-files/0001104659-23-108591.rtf%3b%20filename_%3dUTF-8%27%270001104659-23-108591.rtf" type="application/rtf" title="0001104659-23-108591.rtf">Download DOC</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="../../static-files/0001104659-23-108591.pdf%3b%20filename_%3dUTF-8%27%270001104659-23-108591.pdf" type="application/pdf" title="0001104659-23-108591.pdf">Download PDF</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-vnd-ms-excel file--x-office-spreadsheet"> <a href="../../static-files/0001104659-23-108591.xls%3b%20filename_%3dUTF-8%27%270001104659-23-108591.xls" type="application/vnd.ms-excel" title="0001104659-23-108591.xls">Download XLS</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-octet-stream file--general"> <a href="../../sec-filings/sec-filing/8-k/0001104659-23-108591.html" type="application/octet-stream" title="0001104659-23-108591-ex-101-sch---xbrl-taxonomy-extension-schema.xsd">Download XBRL</a></span><span class="filesize"> </span>
</div>
</div></div>
    <XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srrk="../../../scholarrock.com/20231011">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_srrk_scholarrock.com_20231011 -->
<!-- Field: Set; Name: xdx; ID: xdx_047_20231011_20231011 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001727196 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2023-10-11" name="dei:EntityCentralIndexKey">0001727196</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-10-11" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="#srrk-20231011.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2023-10-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-11</xbrli:startDate>
        <xbrli:endDate>2023-10-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>UNITED STATES<br />
SECURITIES AND EXCHANGE COMMISSION<br />
Washington, D.C. 20549</b></span></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 20%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><b>FORM <span id="xdx_902_edei--DocumentType_c20231011__20231011_zlJpfeDHQHH7"><ix:nonNumeric contextRef="AsOf2023-10-11" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 20%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt">CURRENT REPORT</p>

<p style="font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</p>

<p style="font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Date of Report (Date of earliest event Reported): <span id="xdx_90B_edei--DocumentPeriodEndDate_c20231011__20231011_zid3UfNEGzWe"><ix:nonNumeric contextRef="AsOf2023-10-11" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">October 11, 2023</ix:nonNumeric></span>
</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 14pt"><b><span id="xdx_901_edei--EntityRegistrantName_c20231011__20231011_ztmnvCIKnBuf"><ix:nonNumeric contextRef="AsOf2023-10-11" name="dei:EntityRegistrantName">Scholar Rock Holding Corporation</ix:nonNumeric></span></b></span><br />
(Exact Name of Registrant as Specified in Charter)</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">
<tr style="vertical-align: top">
    <td style="width: 33%; text-align: center"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20231011__20231011_zTeHwxL1PDrc"><ix:nonNumeric contextRef="AsOf2023-10-11" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="width: 34%; text-align: center"><b><span id="xdx_904_edei--EntityFileNumber_c20231011__20231011_zM3VkOZHodl9"><ix:nonNumeric contextRef="AsOf2023-10-11" name="dei:EntityFileNumber">001-38501</ix:nonNumeric></span></b></td>
    <td style="width: 33%; text-align: center"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20231011__20231011_zBGndHXwMA67"><ix:nonNumeric contextRef="AsOf2023-10-11" name="dei:EntityTaxIdentificationNumber">82-3750435</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">(State or Other Jurisdiction of <br />
Incorporation)</td>
    <td style="text-align: center">(Commission File Number)</td>
    <td style="text-align: center">(I.R.S. Employer Identification <br />
Number)</td></tr>
<tr style="vertical-align: top">
    <td rowspan="1">&#160;</td>
    <td rowspan="1">&#160;</td>
    <td rowspan="1">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><b><span id="xdx_908_edei--EntityAddressAddressLine1_c20231011__20231011_zodp3Cx2xv63"><ix:nonNumeric contextRef="AsOf2023-10-11" name="dei:EntityAddressAddressLine1">301 Binney Street</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressAddressLine2_c20231011__20231011_zXbEAwTwyHK8"><ix:nonNumeric contextRef="AsOf2023-10-11" name="dei:EntityAddressAddressLine2">3rd Floor</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressCityOrTown_c20231011__20231011_zOngGyMjvmdd"><ix:nonNumeric contextRef="AsOf2023-10-11" name="dei:EntityAddressCityOrTown">Cambridge</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20231011__20231011_zjrO46qBDva1"><ix:nonNumeric contextRef="AsOf2023-10-11" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressPostalZipCode_c20231011__20231011_zbQune14BHQj"><ix:nonNumeric contextRef="AsOf2023-10-11" name="dei:EntityAddressPostalZipCode">02142</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="text-align: center">(Address of Principal Executive Offices) (Zip Code)</td></tr>
</table>
<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>(<span id="xdx_909_edei--CityAreaCode_c20231011__20231011_zHa5pZKQzMre"><ix:nonNumeric contextRef="AsOf2023-10-11" name="dei:CityAreaCode">857</ix:nonNumeric></span>) <span id="xdx_903_edei--LocalPhoneNumber_c20231011__20231011_zip4mtWRL4Bb"><ix:nonNumeric contextRef="AsOf2023-10-11" name="dei:LocalPhoneNumber">259-3860</ix:nonNumeric></span></b></span></p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Registrant's telephone
number, including area code)</p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Former name or
former address, if changed since last report)</p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #000000; margin-top: 0pt; margin-bottom: 0pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">
<tr style="vertical-align: top">
    <td style="width: 0.35in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Wingdings"><span id="xdx_90B_edei--WrittenCommunications_c20231011__20231011_z3tJCTVkPWGb"><ix:nonNumeric contextRef="AsOf2023-10-11" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings"><span id="xdx_909_edei--SolicitingMaterial_c20231011__20231011_zrAIoaEnctl7"><ix:nonNumeric contextRef="AsOf2023-10-11" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings"><span id="xdx_908_edei--PreCommencementTenderOffer_c20231011__20231011_zhIvelsKi7Ec"><ix:nonNumeric contextRef="AsOf2023-10-11" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20231011__20231011_zNfdbsDp0fi1"><ix:nonNumeric contextRef="AsOf2023-10-11" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
</table>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 1pt; vertical-align: top; width: 35%; text-align: center"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 1pt; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="border: Black 1pt solid; padding: 1pt; width: 33%; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange
    on which registered</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 1pt 1pt 1pt 5.4pt; vertical-align: middle; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_edei--Security12bTitle_c20231011__20231011_zu4fn5isqaUg"><ix:nonNumeric contextRef="AsOf2023-10-11" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 1pt 1pt 1pt 5.4pt; vertical-align: middle; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20231011__20231011_zliUaMzVHcwl"><ix:nonNumeric contextRef="AsOf2023-10-11" name="dei:TradingSymbol">SRRK</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 1pt 1pt 1pt 5.4pt; vertical-align: middle; text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_edei--SecurityExchangeName_c20231011__20231011_zepWUNavmmq6">
    <ix:nonNumeric contextRef="AsOf2023-10-11" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>


<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR &#167;240.12b-2). Emerging growth company <span id="xdx_903_edei--EntityEmergingGrowthCompany_c20231011__20231011_z15N984qL3f6" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2023-10-11" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#120;</ix:nonNumeric></span></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">If an emerging growth company, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span id="xdx_908_edei--EntityExTransitionPeriod_c20231011__20231011_z3ii72McT4A7"><ix:nonNumeric contextRef="AsOf2023-10-11" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod">&#120;</ix:nonNumeric></span></span></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="white-space: nowrap; vertical-align: top; width: 10%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 7.01.</b></span></td>
    <td style="width: 90%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation FD Disclosure.</b></span></td></tr>
  </table>
<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">On October 11,
2023,&#160;Scholar Rock Holding Corporation&#160;(the &#8220;Company&#8221;) issued a press release announcing plans to expand into
cardiometabolic disorders and advance its anti-myosatin program into cardiometabolic disorders and SRK-439, a novel investigational
myostatin inhibitor, for the treatment of obesity towards the filing of an Investigational New Drug Application in 2025. A copy of
the press release is attached hereto as Exhibit 99.1.</p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">The information in this
Item 7.01 of Form 8-K, including the accompanying Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of such section,
nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless
of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.</p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="white-space: nowrap; vertical-align: top; width: 10%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 8.01.</b></span></td>
    <td style="width: 90%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other Events.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Company has also made available a slide
presentation relating to its cardiometabolic disorders program, a copy of which is attached as Exhibit 99.2 to this Current Report on
Form 8-K and is incorporated herein by reference. The Company undertakes no obligation to update, supplement or amend the materials attached
hereto as Exhibit 99.2.</p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="white-space: nowrap; vertical-align: top; width: 10%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01.</b></span></td>
    <td style="width: 90%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 6%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>No.</b></p></td>
    <td style="vertical-align: bottom; width: 94%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td><a href="#tm2328106d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td><a href="#tm2328106d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by the Company on October 11, 2023, furnished herewith.</span></a></td></tr>
  <tr>
    <td><a href="#tm2328106d1_ex99-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2 </span></a></td>
    <td><a href="#tm2328106d1_ex99-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Presentation Slide Deck</span></a></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scholar Rock Holding Corporation</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 47%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 11, 2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Junlin Ho</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Junlin Ho</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General Counsel and Corporate Secretary</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>

<!-- Mirrored from investors.scholarrock.com/node/9636/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:07:48 GMT -->
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6PbTOH9judOgQp8gQ8bZsUYpbM9L690i+pXVDDIGQnPPlCBGKjFa6RobTosjhgE1bK4dQ4BkZTYneka43CfhZ4EVbx8q4bv2BKXkGPTMdjEt/75x3bbFKQM6GMh5GEmScTGKYb0Xw1VMyZ12hcVrVoEwFe6aWNTrFr/7DQT3JUPPqko7IVpNJYDSQvfyGSI4i2NFdPYivFvI8FUHYVSAyplv7jblZRw0sa2x8lu3Rfwcf3fxJGQ== -->
</XBRL>
<div><a name="tm2328106d1_ex99-1.htm"></a></div><HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Scholar
Rock TO ADVANCE ANTIMYOSTATIN PROGRAM to develop novel therapies for CARDIOMETABOLIC DISORDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Company plans to expand into cardiometabolic disorders, leveraging its
experience in myostatin inhibition</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Preclinical data support advancing SRK-439, a novel investigational myostatin
inhibitor for the treatment of cardiometabolic disorders, with an initial focus on obesity, towards an IND in 2025</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>To inform the development of SRK-439, Company plans to initiate a Phase
2 proof-of-concept trial of apitegromab in obesity in 2024 with data readout expected in mid-2025</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Data from pivotal Phase 3 SAPPHIRE trial in SMA expected in Q4 2024</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">CAMBRIDGE, Mass., October 11, 2023
 (BUSINESS WIRE) --&nbsp;</FONT>Scholar Rock&nbsp;(NASDAQ: SRRK), a Phase 3, clinical-stage
biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today
announced it plans to advance SRK-439, a novel investigational myostatin inhibitor for the treatment of obesity towards an investigational
new drug application (IND) in 2025. As part of the Company&rsquo;s strategy to advance the development of SRK-439, it intends to initiate
a Phase 2 proof-of-concept trial with apitegromab in combination with GLP-1 receptor agonist (GLP-1 RA) in 2024. Data from the clinical
trial are expected in mid-2025 and will be used to inform further clinical development of SRK-439.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;As a long-standing leader in targeting myostatin with a highly
selective antibody platform, we are excited to advance our cardiometabolic program. We have discovered multiple, highly selective myostatin
inhibitors and see potential with SRK-439 to retain lean muscle mass, a concern that is commonly associated with weight loss strategies,
including treatments currently on the market for obesity, a common, serious and costly public health issue affecting adults and children
globally. As apitegromab has shown to date in spinal muscular atrophy (SMA), muscle-targeted therapies that are well tolerated have the
potential to represent a new class of treatments across a wide range of diseases,&rdquo; said Jay Backstrom, M.D., M.P.H., President and
Chief Executive Officer of Scholar Rock. &ldquo;While we continue to expand the development of our pipeline, our top priority remains
advancing the apitegromab program in SMA. We recently completed full enrollment of the pivotal Phase 3 SAPPHIRE trial of apitegromab in
SMA, for which we expect to read out topline data in Q4 2024.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Cardiometabolic program</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Muscle plays a key role in metabolic functions and energy homeostasis.
Leveraging proven expertise in anti-myostatin and its effect on increasing muscle mass, the Company has been developing myostatin-selective
inhibitors to address cardiometabolic disorders, including obesity. Scholar Rock&rsquo;s platform has generated multiple antibody candidates,
including apitegromab, that selectively target pro- and latent forms of myostatin. The Company believes the selectivity of these antibody
candidates enables a favorable risk-benefit profile for patients with cardiometabolic disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SRK-439, a novel anti-myostatin antibody candidate developed by Scholar
Rock, has attractive properties, including high <I>in vitro</I> affinity for pro- and latent myostatin, maintenance of myostatin specificity
(i.e., no GDF11 or Activin-A binding), and robust <I>in vivo</I> efficacy in preclinical models. Studies in diet-induced obese mice
showed that SRK-439 in combination with GLP-1 receptor agonist (GLP-1 RA) achieved:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Dose-dependent reversal of lean mass loss during GLP-1-RA mediated
                                                                                                                                                                                             weight loss; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Enhancement of fat mass loss mediated by GLP-1 RA treatment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Cardiometabolic disorders are creating growing global medical
challenges and contribute to the development of serious health conditions, such as cardiovascular disease, Type 2 diabetes, and certain
cancers,&rdquo; said Mo Qatanani, Ph.D., Senior Vice President and Head of Research. &ldquo;Leveraging our unique scientific platform,
Scholar Rock has developed SRK-439 with a proposed mechanism of action that aims to safely maintain muscle mass, while enhancing body
fat loss, thereby potentially enhancing metabolic health and potentially offering a unique opportunity to address a high unmet need in
treating metabolic conditions, including obesity. We look forward to presenting preclinical data on this new asset from our pipeline at
upcoming scientific conferences.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About&nbsp;Scholar Rock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scholar Rock&nbsp;is a clinical-stage biopharmaceutical company focused
on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors
plays a fundamental role.&nbsp;Scholar Rock&nbsp;is creating a pipeline of novel product candidates with the potential to transform the
lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock&rsquo;s
approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a&nbsp;proprietary platform&nbsp;for
the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level.
By developing product candidates that act in the disease microenvironment, Scholar Rock intends to avoid the historical challenges associated
with inhibiting growth factors for therapeutic effect.&nbsp;Scholar Rock&nbsp;believes its focus on biologically validated growth factors
may facilitate a more efficient development path.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scholar Rock<SUP>&reg;</SUP> is a registered trademark of Scholar
Rock,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains &quot;forward-looking statements&quot;
within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar
Rock&rsquo;s future expectations, plans and prospects, including without limitation, any development plans, strategy and progress for
apitegromab and SRK-439, the timing of its clinical trials, anticipated clinical data, and therapeutic benefits for apitegromab and SRK-439,
and other product candidates and indication selection and development timing, the ability of any product candidate to perform in humans
in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of apitegromab, SRK-439 and its
other product candidates and its proprietary platform.&nbsp;The use of words such as &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;could,&rdquo;
 &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
 &ldquo;project,&rdquo; &ldquo;intend,&rdquo; &ldquo;future,&rdquo; &ldquo;potential,&rdquo; or &ldquo;continue,&rdquo; and other similar
expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation,
expectations regarding the therapeutic potential of SRK-439 for the treatment of obesity, planned timing for an IND submission for SRK-439,
that preclinical and clinical data, including the results from the Phase 2 clinical trial of apitegromab and preclinical studies of SRK-439,
are not predictive of, may be inconsistent with, or more favorable than, data generated from future clinical trials of the same product
candidates, including, without limitation, the Phase 3 clinical trial of apitegromab in SMA and preclinical studies of SRK-439, Scholar
Rock&rsquo;s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on
the expected timeline, the data generated from Scholar Rock&rsquo;s SAPPHIRE Phase 3 clinical trial, information provided or decisions
made by regulatory authorities, Scholar Rock&rsquo;s dependence on third parties for development and manufacture of product candidates
including, without limitation, to supply any clinical trials, as well as those risks more fully discussed in the section entitled &quot;Risk
Factors&quot; in Scholar Rock&rsquo;s Quarterly Report on Form&nbsp;10-Q for the quarter ended&nbsp;June&nbsp;30, 2023, as well as discussions
of potential risks, uncertainties, and other important factors in Scholar Rock&rsquo;s subsequent filings with the&nbsp;Securities and
Exchange Commission. Any forward-looking statements represent Scholar Rock&rsquo;s views only as of today and should not be relied upon
as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and&nbsp;Scholar
Rock&nbsp;undertakes no duty to update this information unless required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Scholar Rock:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investors</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rushmie Nofsinger&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scholar Rock&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">rnofsinger@scholarrock.com&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ir@scholarrock.com&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">857-259-5573</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Molly MacLeod&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scholar Rock&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>mmcleod@scholarrock.com</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">media@scholarrock.com&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">802-579-5995</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
<div><a name="tm2328106d1_ex99-2.htm"></a></div><HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img001.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">|   CONFIDENTIAL AND PROPRIETARY Introduction of Scholar  Rock&#8217;s Cardiometabolic  Disorders Program Optimizing weight loss by  preserving and increasing lean  muscle mass with a highly  selective myostatin inhibitor </P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img002.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">&#169; Scholar Rock, Inc. All rights reserved. 2023.  Forward - Looking Statements Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock, Inc. (&#8220;Schol ar  Rock&#8221;), including without limitation, Scholar Rock&#8217;s expectations regarding  its strategy, its product candidate selection and development timing, including timing for the initiation of and reporting re sul ts from its  preclinical and clinical trials for  SRK - 439, apitegromab , SRK - 181, and  other product candidates and indication selection and development timing,  its cash runway, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical,  preclinical or clinical trial data, and the potential of its product candidates and proprietary platform. The use of words su ch  as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221;  &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; and other similar expressions are intended to identify su ch forward - looking statements  for the purposes of the safe harbor provisions  under The Private Securities Litigation Reform Act of 1995. All such forward - looking statements are based on management's current expectations of future events and are subject to a number of risks  and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by su ch  forward - looking statements. These risks and uncertainties include, without  limitation, that preclinical and clinical data, including the results from the Phase 2 trial of  apitegromab or Part A of the Phase 1 trial of SRK - 181, are not predictive of, may be inconsistent with, or more  favorable than, data generated from future clinical trials of the same product candidate, including the Phase 3 clinical tria l o f  apitegromab in SMA and Part B of the Phase 1 clinical trial of SRK - 181,  respectively, Scholar Rock&#8217;s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from  Scholar Rock&#8217;s nonclinical and preclinical studies and clinical trials, information provided or decisions made by regulatory  aut horities, competition from third parties that are developing products for similar  uses, Scholar Rock&#8217;s ability to obtain, maintain and protect its intellectual property, the success of Scholar Rock&#8217;s current an d potential future collaborations, Scholar Rock&#8217;s dependence on third parties  for development and manufacture of product candidates including, without limitation, to supply any clinical trials, Scholar R ock &#8217;s ability to manage expenses and to obtain additional funding when needed  to support its business activities and establish and maintain strategic business alliances and new business initiatives, and  the impacts of current macroeconomic and geopolitical events, hostilities in  Ukraine, increasing rates of inflation and rising interest rates, on business operations and expectations, as well as those r isk s more fully discussed in the section entitled "Risk Factors" in Scholar Rock&#8217;s  Form 10 - K for the year  ended December 31, 2022, and  Quarterly Report on Form 10 - Q for the quarter ended  June 30 , 2023, as well as discussions of potential risks, uncertainties, and other important  factors in Scholar Rock&#8217;s subsequent filings with the Securities and Exchange Commission. Any forward - looking statements repres ent Scholar Rock&#8217;s views only as of today and should not be relied upon  as representing its views as of any subsequent date. All information in this press release is as of the date of the release,  and Scholar Rock und ertakes no duty to update this information unless required by  law. This presentation and the accompanying oral presentation may also contain estimates and other statistical data made by indepe nde nt parties and by us relating to market size and growth and other data  about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight  to such estimates. In addition, projections, assumptions, and estimates of  our future performance and the future performance of the markets in which we compete are necessarily subject to a high degree of uncertainty and risk. Apitegromab , SRK - 181 and SRK - 439 are investigational drug candidates under evaluation. Apitegromab , SRK - 181 and SRK - 439  have not been approved for any use by the FDA or any other regulatory  agency and the safety and efficacy of apitegromab and SRK - 181 have not been established.</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img003.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">&#169; 2023 Scholar Rock, Inc. All rights reserved. Scholar Rock:  Transforming  Patient Lives,  Addressing  High Unmet  Medical Need 3 &#8226; Global leader in TGF &#946; superfamily biology &#8226; Targeting the latent forms of growth factors &#8226; Exquisite selectivity to deliver differentiated  therapies Revolutionary  Platform &#8226; Phase 3 SAPPHIRE study underway, enrollment  completed in Q3 2023; data readout expected in Q4 2024 &#8226; Phase 1 proof - of - concept DRAGON  trial in  immuno - oncology:  enrollment expected to be  completed in Dec 2023 &#8226; Advance Ca rdiometabolic Program: &#8226; Plan to initiate proof of concept trial in obesity  with  apitegromab in combination with GLP - 1 RA  in 2024 &#8226; Plan to concurrently advance SRK - 439, a novel  investigational anti - myostatin antibody  towards IND submission in 2025 Neuromuscular  and Beyond &#8226; Compelling proof - of - concept TOPAZ data  with  apitegromab in spinal muscular atrophy (SMA)  informed Phase 3 SAPPHIRE  trial design &#8226; Seasoned leadership team with track record of  clinical and commercial success Positioned for Success</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img004.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White"> &#169; 2023 Scholar Rock, Inc. All rights reserved. Revolutionary Approach to Regulating TGF &#946; Superfamily Implicated in  Devastating Diseases 4 Scholar Rock&#8217;s R&amp;D Platform Goals Aiming to Transform Medical Practice &#8226; Selectively target the latent form of growth factors in the  microenvironment of cells and tissues with uniquely designed antibodies &#8226; Overcome the challenges that plague traditional approaches that target  the &#8220;mature&#8221;  active growth factor or its receptors, which are difficult to  differentiate and lead to unintended negative effects Scholar Rock&#8217;s Target Latent G rowth Factor Traditional Target &#8220;mature&#8221;  active growth factor TGF &#946; Superfamily: Highly Sought - After Targets  Dysregulation plays a role in  devastating diseases that have a  high unmet need, including: &#8226; Neuromuscular disorders  &#8226; Fibrosis &#8226; Oncology Recognized by the industry as  important targets given their  fundamental roles in regulating a  variety of biological processes</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img005.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White"> &#169; 2023 Scholar Rock, Inc. All rights reserved. Differentiated  Expertise  Developing Muscle - Targeted Therapies 5 Next Frontier in  Antimyostatin Leveraging Our R&amp;D Platform to Expand into Cardiometabolic  Disorders &#8226; Pioneered unique approach to develop antibodies that bind to pro - and latent forms of myostatin with exquisite selectivity and inhibit its  activation &#8226; Apitegromab is being developed as a highly selective inhibitor of latent  myostatin activation, to enhance muscle growth and function in  neuromuscular disorders &#8226; To date  apitegromab has been evaluated in approximately 250 patients  ages 2 to 21 living with spinal muscular atrophy (SMA), showing sustained  benefit over 36 months, a well tolerated profile and low discontinuation  rate &#8226; Discovered multiple additional anti - pro/latent myostatin inhibitory  antibodies including: &#8226; SRK - 439: Being developed as a novel, highly potent and selective antibody  tailored for cardiometabolic disorders Myostatin is a member of the TGF &#946; superfamily known to be a negative  regulator of muscle mass and promotes  muscle catabolism</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img006.jpg" ALT="" STYLE="height: 844px; width: 1500px"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">&#169; 2023 Scholar Rock, Inc. All rights reserved. Potential to transform the lives of people living with a wide range of serious diseases, including neuromuscular disorders, cardiometabolic, oncology, and fibrosis TARGET DISCOVERY/ PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ANTICIPATED KEY  MILESTONES Latent Myostatin SPINAL MUSCULAR ATROPHY Apitegromab SAPPHIRE Data Readout 2024 Commercial Launch 2025* CARDIOMETABOLIC DISORDERS Apitegromab in Obesity** File IND Initiate Ph 2 POC trial in 2024 SRK - 439 (novel antimyostatin antibody) IND - enabling studies in 2024 File IND in 2025 Latent TGF &#946; - 1 IMMUNO - ONCOLOGY SRK - 181 (selective context - independent,  anti - latent TGF &#946; - 1) Rolling clinical data updates FIBROSIS Selective context - dependent  (LTBP1 &amp; LTBP3) anti - latent TGF &#946; - 1 IND - enabling studies RGMc ANEMIA Selective anti - RGMc IND - enabling studies Robust Pipeline of Novel Product Candidates  6 LTBP3=latent transforming growth factor beta binding protein 3; LTBP1=Latent Transforming Growth Factor Beta Binding Protein  1;  RGM=Repulsive  guidance molecule; TGF &#946; - 1 =Transforming Growth Factor Beta - 1 ;  IND = Investigational New Drug; POC = Proof of Concept * Contingent upon receipt of regulatory approval; ** Ph1 studies in healthy volunteers have been completed.</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img007.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White"> &#169; 2023 Scholar Rock, Inc. All rights reserved. Next Horizon: Cardiometabolic Disorders</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img008.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">8 Obesity is a common, serious, and costly chronic  disease affecting adults and children worldwide Obesity is Recognized as a Top Global Public Health Issue By 2030, obesity will affect  &gt; 1 billion  adults and  &gt;250  million  children and  adolescents 1 In the US,  1 in 5  children and  more than  1 in 3  adults  are obese Obesity can  increase the risk  of comorbidities,  such as some  cancers, heart  disease, and type  2 diabetes 1 The World Obesity Foundation, World Obesity Atlas 2022;  2 Centers for Disease Control and Prevention (CDC) Obesity Facts, www.cdc.gov/obesity/about - obesity, accessed August 30,  2023;  3  Ward ZJ, Bleich SN, Long MW,  Gortmaker SL (2021) Association of body mass index with health care expenditures in the United States by age and sex.  PLoS ONE 16(3):  e0247307 Adult obesity associated with more than  $170 billion  in excess costs  annually in the U.S. 3</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img009.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">9 Loss of Lean Muscle Is Significant with GLP - 1 RA Therapies  Lean muscle is essential to healthy metabolic function &amp; body composition  Situation &#8226; Significant challenges with current weight loss strategies  (dietary/behavioral, pharmacological, surgical),  including tolerability, lack  of durability and significant muscle loss  1,2,3 &#8226; Recently  approved GLP - 1 receptor agonists  (GLP - 1 RAs) are highly  effective in weight loss &amp; experiencing rapid uptake &#8226; However,  25% - 40% of total body weight loss  mediated by GLP - 1 RA  therapy  may be attributed to loss of lean muscle mass 2,3 &#8226; Preserving lean muscle mass  is important to promote long - term metabolic  benefits, sustainable weight management and health outcomes 4,5,6,7 Significant proportion of  weight loss due to loss of  lean muscle mass  1 Muller TD, et al Anti - obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery 2022; 21, 201 &#8211; 223 ; 2 Wil ding JPH,  Batterham RL,  Calanna S, et al. Once - Weekly  Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989 - 1002; 3  Jastreboff AM, et al  Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022; 387 (3):  205 - 216 ;  4 Cava et al. Preserving healthy muscle during weight loss. Adv  Nutr 2017;8:511 - 19. ;  5 Lundgren JR et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide or Both  Combined. NEJM 2021;384:1719 - 30. ;  6 Beal JW et al. Dietary weight loss - induced improvements in metabolic function are enhanced by exercise in people with obesity  and prediabetes. Nat  Metab . 2022;5(7):1221 - 1235 ;  7  Dulloo AG, et al How dieting makes some fatter: from a perspective of human body composition autoregulation. Proc  Nutr Soc. 2012 Aug;71(3):379 - 89 GLP - 1: glucagon - like peptide - 1</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img010.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">10 Obesity Landscape is Evolving &amp; Growing: Estimated $70 - $100B  Annual Revenues by 2035 1 1.  Seigerman , ED, et al. &#8220;Obesity Exceptionalism: It&#8217;s different this time.&#8221; BMO Capital Markets: September 2023 retatrutide 2010 2014 2017 2021 2023 2025 2022</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img011.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White"> 11 Recent KOL Interviews: Select Physicians See Value and Benefit in  Muscle Maintenance During Weight Loss  &#187; Some  key opinion leaders (KOLs) see a lack of  standard of care (SOC) in obesity  which leads to  significant unmet need in large patient population &#187; KOLs see the potential for additional benefit to  patients as sustained results stem from exercise,  proper diet and treatment &#187; Combination therapy with other weight loss drugs  (GLP - 1 RA) may have a synergistic effect on weight  loss and benefit overall patient health &#187; Patients may experience prolonged weight - loss  and sustained results through the addition of  muscle - targeted therapy Key Opportunities &#8220;There isn&#8217;t a set SOC right now for obesity and there clearly needs to  be something out there that is standard and addresses the entire scope  of the disease. If a company could address both weight loss and muscle  maintenance, I think this could improve SOC significantly.&#8221; - KOL ,  PCP &#8220;I do see the importance of muscle mass, and this is something that if I  could add to my patient&#8217;s program, I would in a heartbeat and really  think it would make an impact. I have a lot of patients that would  benefit from something like this.&#8221; - KOL , Endocrinologist Source : Clarion 2022 Analysis, Clarion KOL interviews</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img012.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">12 We believe Therapeutic Strategy for Safe, Durable Weight Loss  Could Include a Highly Selective Antimyostatin to Retain Lean  Muscle Opportunity &#8226; Inhibition of myostatin has demonstrated important physical  (increased muscle mass) and  beneficial metabolic effects  (insulin sensitivity, basal metabolic rate, reduction in fat mass)  in preclinical models 1 &#8226; Strong evidence has indicated  upstream targeting of  structurally differentiated pro - and latent myostatin leads to  exquisite selectivity  and  avoids undesirable off - target  effects  2 - 4 &#8226; Inhibition of myostatin in combination with GLP - 1 RA - driven  weight loss  may lead to  retention of lean muscle mass and  combat the counter - regulatory metabolic effects of weight loss 1 Yang M et al. Myostatin: A potential therapeutic target for metabolic syndrome. Frontiers in Endocrinology 2023;14:1181913 ; 2 Pirruccello - Straub M et al. Blocking extracellular  activation of myostatin as a strategy for treating muscle wasting. Sci Reports 2017;8:2922;  3 Welsh BT et al. Preclinical safety assessment and  toxicokinetics of apitegromab, an  antibody targeting  proforms of myostatin for the treatment of muscle - atrophying disease. Int J Tox 2021;40(4):322 - 336. ;  4 Barrett D et al. A randomized phase 1 safety,  pharmacokinetic and pharmacodynamic study of a novel myostatin inhibitor apitegromab (SRK - 015): A potential treatment for spinal muscular atrophy. Adv  Ther 2021;38:3203 - 3222. SRRK&#8217;s  antimyostatin antibody </P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img013.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">13 Scholar Rock Antibodies Selectively  Inhibit Activation of  Myostatin Selective Targeting of  Proforms of Myostatin SRRK antibodies do not bind to mature  myostatin or any form of GDF11, Activin A,  or other TGF - &#946; family members Selectivity is critical to avoid safety concerns &#9642; Mature myostatin and mature GDF11 have 90% sequence  conservation &#9642; Most prior myostatin approaches bind/inhibit both myostatin  and GDF11 &#9642; GDF11 loss leads to embryonic lethality, skeletal and kidney  formation defects 1 &#9642; GDF11 signaling inhibition may have negative impacts on  bone 2 Broad inhibition of  ActRIIb signaling may be problematic &#9642; ActRIIB knockout animals die shortly after birth with  developmental defects in respiratory and cardiac organs 3 &#9642; Activins are critical in reproductive biology and inhibition was  shown to reduce FSH levels in women 4 13 1.McPherron AC et al   Nat Genet 1999, 22(3):260 - 264.; 2.  Joonho Suha et al  Proc Natl Acad Sci U S A .  2020 Mar 3;117(9):4910 - 4920 ;  3. Oh SP &amp; Li E. Genes Dev . 1997 Jul 15;11(14):1812 - 26; 4.  Garito T, et al.  Clin Endocrinol (Oxf) . 2018 Jun;88(6):908 - 919 GDF11: Growth and Differentiation factor 11 ;  ActRIIB : Activin Receptor IIB Apitegromab SRK - 439 Pro - GDF - 11 Proactivin Myostatin GDF - 11 Activin A Promyostatin ActRIIB</P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img014.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">&#169; 2023 Scholar Rock, Inc. All rights reserved. SRK - 439 Preclinical Data 14</P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img015.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">15 SRK - 439: New Preclinical Myostatin Inhibitor Candidate Represents  Opportunity to Address Cardiometabolic Patient Population Antibody/ Variant mTLL2 IC 50 ( nM ) mAb K D  ( nM ) SRK - 439 0.145 0.579 &#8226; SRK - 439 , a novel  antimyostatin antibody being developed  by SRRK, has  attractive properties  and  potential to  address muscle loss associated with weight loss &#9642; High  in vitro affinity for pro - and latent myostatin &#9642; Maintained myostatin specificity (No GDF11 or Activin - A  binding) &#9642; Maintained good developability profile &#8226; Amenable to  subcutaneous formulation  and  dosing &#9642; High concentrations achieved with unoptimized standard  buffer Several lead candidates identified  150nM 0.24nM 0 1 2 3 Campaign Screening High Conc    Low Conc A b s ( 4 5 0 n m ) 150nM 0.24nM L o w e r t h e A b s ( 4 5 0 n M ) G r e a t e r A c t i v i t y mTLL2 IC 50 : Inhibitory concentration at 50% as measure of in vitro potency of the antibody in its ability to inhibit the activation of  lat ent myostatin by its activating  enzyme mammalian  tolloid like protease 2 | K D : Equilibrium dissociation constant as a measure of binding affinity of the antibody to latent myostatin.  Represents highest activity of  existing SRRK  antimyostatin antibody at the time of  initiation of the new discovery  campaign Selection of new leads with  activities &#8805; previous antibodies  that were advanced for further  testing</P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img016.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">16 SRK - 439 Maintained Lean Mass in Mouse Diet Induced Obesity (DIO)  Model When Combined with  GLP - 1 RA Therapy -80 -60 -40 -20 0 20 40 60 80 % Change Fat Mass from Baseline (qNMR) %   C h a n g e IgG IgG 3 1 0.3 0.06mg/kg Lira SRK-439 &#9642; Improved fat mass loss vs GLP - 1 RA alone -20 -10 0 10 20 % Change Lean Mass from Baseline (qNMR) %   C h a n g e IgG IgG 3 1 0.3 0.06mg/kg Lira SRK-439 **** **** **** &#9642; Increased lean mass gain vs GLP - 1 RA alone One - way ANOVA *       P&lt; 0.05 **     P&lt; 0.005 ***   P&lt; 0.0005 **** P&lt; 0.0001 Figure shows the effects of increasing doses of SRK - 439 in combination with  liraglutide on fat mass (left panel) and lean mass (right panel)  in a 28 - day DIO mouse model as measured by  qNMR ; statistical analysis was done using one - way ANOVA (Dunnett&#8217;s multiple comparison  test).</P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img017.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">17 SRK - 439 Dose - Dependently Reversed Lean Mass Loss in Mouse DIO  and Enhanced Fat Mass Loss Induced by  Semaglutide Treatment -80 -60 -40 -20 0 20 % Change - Fat Mass (qNMR) %   C h a n g e IgG S R K - 4 3 9 IgG 0.1 0.3 1.0 3.0 SRK-439 (mg/kg) Semaglutide 0.04 mg/kg -20 -10 0 10 20 % Change - Lean Mass (qNMR) %   C h a n g e IgG S R K - 4 3 9 IgG 0.1 0.3 1.0 3.0 SRK-439 (mg/kg) Semaglutide 0.04 mg/kg &#10033; &#10033;&#10033;&#10033;&#10033; One - way ANOVA *       P&lt; 0.05 **     P&lt; 0.005 ***   P&lt; 0.0005 **** P&lt; 0.0001 Figure  showed the effects of increasing doses of SRK - 439 in combination with  liraglutide on fat mass (left panel) and lean mass (right panel)  in DIO mouse model as measured by  qNMR ; statistical analysis was done using one - way ANOVA (Dunnett&#8217;s multiple comparison test). &#9642; Additional fat mass loss vs  semaglutide alone &#9642; Dose - dependent preservation of lean mass  with effects seen as low as 0.3mg/kg</P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img018.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">18 &#9642; Preclinical data suggests mechanism of action  that could  safely reduce body fat while  maintaining muscle , thereby  enhancing metabolic health &#9642; Studies in DIO mice on the effects of GLP - 1 receptor agonist (GLP - 1 RA) in combination with a  myostatin - selective inhibitor showed: &#8211; Dose - dependent reversal of lean mass loss mediated by GLP - 1 RA treatment &#8211; Enhancement of fat mass loss mediated by GLP - 1 RA treatment &#9642; Initial preclinical data for  SRK - 439 , a novel myostatin selective inhibitor, supports an overall  profile for a  differentiated molecule designed to address cardiometabolic patient population &#8211; Potentially suitable for subcutaneous administration &#9642; Filed composition of matter patent for SRK - 439 with projected expiry of 2043 SRRK Selective Myostatin Inhibitors Represent an Opportunity to Address High  Unmet Need in Cardiometabolic Disorders DIO: Diet Induced Obesity / GLP - 1: glucagon - like peptide 1 </P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img019.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">19 Plan to Expedite Cardiometabolic Program with Phase 2 Proof of  Concept Study of Apitegromab in Obesity  SRK - 439 Rapid Proof of Concept Phase 2 Study  with  A pitegromab in combination with GLP - 1  APITEGROMAB While a dvanc ing investigational SRK - 439 for cardiometabolic indication 2023 2024 2025 Apitegromab (SMA) Apitegromab POC ( Cardiomet )  Pipeline: SRK - 439 Enrollment  Completed Q3 SAPPHIRE  Topline Q4* POC study start * POC data  readout * DC candidacy * IND * Potential Commercial  Launch * Expanding  antimyostatin programs creates  additional  potential  milestones in next  18 - 24 months * Anticipated milestones</P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img020.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">&#169; 2023 Scholar Rock, Inc. All rights reserved. 20 &#8226; Preclinical data suggests  selective mechanism of  action  that can maintain  muscle mass while enhancing  fat mass loss, thereby  improving metabolic function &#8226; SRK - 439: Preclinical data  supports the overall target  candidate profile to address  the cardiometabolic patient  population &#8226; Represents a potential new  class of treatment Differentiation &#8226; Strong pre - clinical evidence indicates maintenance  or increase in lean muscle mass &amp; enhancement of  fat loss when a myostatin selective inhibitor is  combined with GLP - 1 receptor agonist (GLP - 1 RA) &#8226; Scholar Rock has the potential to lead the next  frontier in anti - myostatin therapies with  pioneered unique approach and differentiated  expertise Strong Scientific Rationale &#8226; Expanded investments in pipeline, including to  accelerate and advance cardiometabolic program Investment  Opportunity &#8226; Obesity is a growing global epidemic leading to  chronic health problems and 4.7M premature  deaths annually 1 &#8226; Clinical and commercial  landscape evolving quickly  amid high unmet need &#8226; Muscle - targeted approach represents a new  potential class of treatments High Unmet Medical Need &amp; Significant Commercial  Opportunity Cardiometabolic  Program  Summary 1 www.who.int/news - room/fact - sheets/detail/obesity - and - overweight</P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img021.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White"> &#169; 2023 Scholar Rock, Inc. All rights reserved. THANK YOU 21</P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img022.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">&#169; 2023 Scholar Rock, Inc. All rights reserved. APPENDIX 22</P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img023.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">&#169; 2023 Scholar Rock, Inc. All rights reserved. Ongoing SAPPHIRE Phase 3 Trial Overview 23 Randomized, double - blind, placebo - controlled, parallel arm design (n=204) Enrolling patients who are on SMN - directed therapy ( nusinersen or  risdiplam ) Anticipate completing enrollment in 3Q 2023 TREATMENT  (52 weeks) Apitegromab (20 mg/kg IV q4w) + SMN - directed therapy Apitegromab (10 mg/kg IV q4w) + SMN - directed therapy Placebo (IV q4w) + SMN - directed therapy SCREENING MAIN POPULATION  (n=156) Ages 2 - 12 With  nonambulatory Types 2 and 3 SMA N=52 N=52 N=52 R Stratified to ensure balanced allocation  across the three arms:  1. Age at SMN therapy initiation (age &lt; 5 vs age &#8805; 5)  2. SMN therapy ( nusinersen vs.  risdiplam ) ENDPOINTS Primary Efficacy: Mean HFMSE change from baseline at 12 months   Additional Efficacy Measures: RULM, WHO, other outcome measures  Safety, PK/PD, ADA Additional Data Opportunities Exploratory population (age 13 - 21), in patients using SMN therapy Focused upon safety &amp; exploratory efficacy (n=48; 2:1 randomization between  apitegromab 20 mg/kg vs placebo) Separate open - label extension study (after patients complete 12 - month treatment period) Focused upon safety &amp; exploratory long - term efficacy ClinicalTrials.gov Identifier: NCT05156320 HFMSE=Hammersmith Functional Motor Scale Expanded; RULM=Revised Upper Limb Module; R=randomization; SMA=spinal muscular atrop hy; SMN=survival motor neuron.</P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="../../../cdn.kscope.io/e9f26496c0bcd89dd472ee8daca78520-tm2328106d1_ex99-2img024.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White"> &#169; 2023 Scholar Rock, Inc. All rights reserved. Executing on the Promise:  Apitegromab SMA Trials 24 SMA=Spinal Muscular Atrophy *Subject to regulatory approval    WHERE WE ARE Phase 3 12 - Month IN PROCESS Long - term EXTENSION 2023  enrollment  completed Q4  2024  data 2025  launch*  ANTICIPATED MILESTONES  WHERE WE WERE  Phase 2 12 - Month COMPLETE 24 - Mont h EXTENSION COMPLETE 36 - Month EXTENSION COMPLETE  WHERE WE  PLAN TO GO Ambulatory  patients Under 2 Years of Age  (including those treated  with gene therapy)</P>

<!-- Field: Page; Sequence: 24; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>


  </div>

  </div>

          <script type="text/javascript">var s_CCSWebHostingAccount = "trcgscholarrock";</script>
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/9636\/html","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb56236\/themes\/site\/nir_pid2662"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"user":{"uid":0,"permissionsHash":"4506f7b957b4baf2488ee006e9b884f3b49293f46cfb6e03ffbb15fedba12da4"}}</script>
<script src="../../sites/g/files/knoqqb56236/files/js/js_D31miEwayYNfIODJWy2ump8i_gwklTzvOKq4eFgXiKw4996.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl"></script>
<script src="../../../assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" crossorigin="anonymous" async integrity="sha384-9QSqHMB+yiy/V4i+d2Au+ydEWbBz4E9DqsE+oYKOnL+kj4XAZGYZxabd0P3OGHkf"></script>

  </body>
</html>
